- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Omeros Corp
+ Add to WatchlistOMER:US
5.3000 USD 0.2200 4.33%
Share
As of 20:10:00 ET on 05/24/2013.
More on OMER
News for Omeros Corp (OMER)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Largest Nasdaq Short Interest Percent Increases as of April 30
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- AeroVironment, F5 Networks, Romarco, Wynn: U.S. Equity Movers
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Concho, Discover Financial, Fresh Market: U.S. Equity Movers
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Paul Allen's Vulcan Capital to Invest in Omeros Biotechnology Drug Program
- Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease Published May 23, 2013
- Omeros to Present at Two Upcoming Conferences Published May 22, 2013
- Motor Neurone Diseases Pipeline Examined in Insightful Global Markets Direct Report Available at MarketPublishers.com Published May 21, 2013
- Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock Published May 14, 2013
- Omeros Corporation Reports First Quarter 2013 Financial Results Published May 10, 2013
- Omeros Announces $16.2 Million Registered Direct Offering of Common Stock Published May 09, 2013
- Omeros Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease Published May 01, 2013
- Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review Published Apr 30, 2013
- Omeros Reports OMS302 Clinical Data Presented at the Annual ASCRS and ASOA Symposium and Congress Published Apr 25, 2013
- Siga Ruled Liable for Breaking PharmAthene Drug Contract
- Alex Denner Joins Vivus Activist Slate in Post-Icahn Move
- MS Patients Choose Death Risk With Potent Drug Treatment
- Elan Board Unanimously Rejects $6.4 Billion Takeover Offer
- Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail
- Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Says
- Addex Rises on Positive Rodent Experiment Results: Zurich Mover
- Novartis Sees MorphoSys Muscle-Atrophy Drug as Exciting
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
- Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
- U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer
- Largest Weekly Option Sentiment Changes for S&P 500 Companies
- SAC Digs In as Deadline Nears for U.S. Insider Cases
- Japan Biotech Firms Jump as Abenomics Cash Spurs Speculation
- Puma Biotech Gains After Rival Drug Data Show No Threat
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page